Cue Biopharma (NASDAQ:CUE) Downgraded by Zacks Investment Research to “Hold”

Cue Biopharma (NASDAQ:CUE) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, ValuEngine downgraded Cue Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th.

Shares of NASDAQ:CUE traded down $0.01 during midday trading on Tuesday, reaching $15.78. 132,544 shares of the company’s stock traded hands, compared to its average volume of 249,522. Cue Biopharma has a one year low of $4.69 and a one year high of $17.99. The stock has a 50 day moving average of $14.39 and a 200 day moving average of $9.71. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.17 and a current ratio of 3.17. The company has a market cap of $363.01 million, a price-to-earnings ratio of -8.13 and a beta of 1.65.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.13. Cue Biopharma had a negative return on equity of 148.66% and a negative net margin of 1,437.96%. The company had revenue of $0.98 million for the quarter. Sell-side analysts predict that Cue Biopharma will post -1.72 EPS for the current fiscal year.

In other Cue Biopharma news, Director Christopher A. Marlett sold 4,000 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $17.00, for a total value of $68,000.00. Following the transaction, the director now owns 9,000 shares of the company’s stock, valued at $153,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Christopher A. Marlett sold 9,000 shares of the firm’s stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $17.24, for a total value of $155,160.00. The disclosure for this sale can be found here. In the last three months, insiders sold 42,732 shares of company stock worth $690,664. 16.80% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System raised its stake in shares of Cue Biopharma by 8.4% in the third quarter. California State Teachers Retirement System now owns 30,549 shares of the company’s stock worth $258,000 after buying an additional 2,374 shares during the period. Barclays PLC raised its stake in shares of Cue Biopharma by 22.4% in the third quarter. Barclays PLC now owns 14,235 shares of the company’s stock worth $120,000 after buying an additional 2,603 shares during the period. Northern Trust Corp raised its stake in shares of Cue Biopharma by 2.0% in the second quarter. Northern Trust Corp now owns 204,555 shares of the company’s stock worth $1,839,000 after buying an additional 3,970 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Cue Biopharma in the third quarter worth about $67,000. Finally, Sigma Planning Corp raised its stake in shares of Cue Biopharma by 25.9% in the third quarter. Sigma Planning Corp now owns 60,210 shares of the company’s stock worth $508,000 after buying an additional 12,405 shares during the period. 26.45% of the stock is currently owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Featured Article: How To Calculate Debt-to-Equity Ratio

Get a free copy of the Zacks research report on Cue Biopharma (CUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.